NCT00450658View on ClinicalTrials.gov

Efficacy and Safety Study of HZT-501 in Reducing the Risk of Ibuprofen-associated Ulcers

PHASE3CompletedINTERVENTIONAL

Enrollment

627

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2008

Conditions

Peptic Ulcer

Interventions

DRUG

HZT-501

HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks

DRUG

Ibuprofen

Ibuprofen 800mg orally 3 times daily for 24 weeks

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Amgen

INDUSTRY